Exenatide Effects On Vascular Endothelial Function And Cardiovascular Disease Risk Factors In Patients With Type 2 Diabetes

Objective:To investigate the effects of the exenatide on vascular endothelial function and cardiovascular risk factors in patients with type 2 diabetes mellitus.Methods: The patients with type 2 diabetes were randomly divided into two groups,one group as the control group,given diet guidance,adjust dietary structure,reasonable exercise;A group of exenatide treatment group,exenatide subcutaneous injection therapy,4 weeks ago,5ug/ times,before breakfast and dinner each time,after 8 weeks,10ug/ times,morning and evening meal before each time,a total of 12 weeks;endothelial function related indexes were observed before and after treatment,such as soluble intercellular adhesion molecule(sICAM-1),soluble vascular cell adhesion molecule(sVCAM-1)and monocyte chemotactic factor(MCP-1),brachial artery flow mediated guide vasodilation(FMD)before and after treatment;while monitoring the metabolic indicators related to cardiovascular disease,such as fasting blood glucose,fasting C peptide,glycosylated hemoglobin(HbAc1),total cholesterol,triglyceride,low density lipoprotein cholesterol,High density lipoprotein cholesterol,body weight,body mass index,waist circumference.Results: The control group before and after treatment,sICAM-1,sVCAM-1,MCP-1 and FMD levels showed no significant difference(P>0.05);theexenatide group after 12 weeks of treatment compared with before treatment,sICAM-1,sVCAM-1,MCP-1 decreased,FMD increased,and the difference was statistically significant(P<0.05);after 12 weeks of treatment with exenatide group,the levels of sICAM-1,s VCAM-1 and MCP-1 were lower(P<0.05)and FMD(P<0.05)was higher than that in the control group.Compared before and after treatment in the control group,no statistically significant difference in fasting blood glucose,glycosylated hemoglobin(HbAc1),total cholesterol,triglyceride,low density lipoprotein cholesterol,body weight,BMI,waist circumference,fasting C peptide level(P>0.05);Exenatide group after 12 weeks of treatment compared with before treatment,fasting blood glucose,glycosylated hemoglobin(HbAc1),total cholesterol,triglyceride,low density lipoprotein cholesterol,body weight,body mass index,abdominal circumference decreased,fasting C peptide levels increased,and the difference was statistically significant(P<0.05);two groups of high density lipoprotein cholesterol showed no significant difference(P>0.05).Conclusion:Exenatide can improve the metabolic disorder associated with cardiovascular disease and protect the vascular endothelial function.Exenatide can prevent and reduce the occurrence and development of cardiovascular events to some extent.